Enhanced glycolysis and HIF-1α activation in adipose tissue macrophages sustains local and systemic interleukin-1β production in obesity

Monika Sharma1, Ludovic Boytard2, Tarik Hadi2, Graeme Koelwyn3, Russell Simon1, Mireille Ouimet1, Lena Seifert2, Westley Spiro1, Bo Yan1, Susan Hutchison1, Edward A. Fisher1, Ravichandran Ramasamy1, Bham Ramkhalawon2* & Kathryn J. Moore1*

During obesity, macrophages infiltrate the visceral adipose tissue and promote inflammation that contributes to type II diabetes. Evidence suggests that the rewiring of cellular metabolism can regulate macrophage function. However, the metabolic programs that characterize adipose tissue macrophages (ATM) in obesity are poorly defined. Here, we demonstrate that ATM from obese mice exhibit metabolic profiles characterized by elevated glycolysis and oxidative phosphorylation, distinct from ATM from lean mice. Increased activation of HIF-1α in ATM of obese visceral adipose tissue resulted in induction of IL-1β and genes in the glycolytic pathway. Using a hypoxia-tracer, we show that HIF-1α nuclear translocation occurred both in hypoxic and non-hypoxic ATM suggesting that both hypoxic and pseudohypoxic stimuli activate HIF-1α and its target genes in ATM during diet-induced obesity. Exposure of macrophages to the saturated fatty acid palmitate increased glycolysis and HIF-1α expression, which culminated in IL-1β induction thereby simulating pseudohypoxia. Using mice with macrophage-specific targeted deletion of HIF-1α, we demonstrate the critical role of HIF-1α-derived from macrophages in regulating ATM accumulation, and local and systemic IL-1β production, but not in modulating systemic metabolic responses. Collectively, our data identify enhanced glycolysis and HIF-1α activation as drivers of low-grade inflammation in obesity.

Obesity and its associated metabolic diseases, insulin resistance and type 2 diabetes, continue to increase in the United States and worldwide1, and fully effective therapies to combat this growing epidemic are lacking. Obesity gives rise to a state of chronic inflammation, which is causally linked to insulin resistance (IR) and type 2 diabetes2–4. In obese mice and humans, there is a striking accrual of macrophages in visceral adipose tissue5,6, and these immune cells are key contributors to obesity-induced insulin resistance5,6. Whereas adipose tissue macrophages (ATM) comprise approximately 10–15% of stromal cells in the lean adipose tissue, during high fat diet feeding the recruitment of monocytes into visceral adipose depots can drive macrophage accumulation up to 50% of all cells in obese adipose tissue7. A number of factors, including adipocyte hypertrophy, increased extracellular lipid concentrations and oxidative stress are thought to drive expression of chemoattractant factors that recruit monocytes in the expanding adipose tissue7. In this metabolically disturbed environment, the monocyte-derived macrophages take on an inflammatory phenotype that is distinct from those of macrophages residing in lean adipose tissue8,9. These ATMs are a source of inflammatory cytokines, particularly TNFα10 and IL-1β11, that sustain the local and systemic inflammation that contributes to insulin resistance [reviewed in1], yet the mechanisms that drive metabolic inflammation and the pro-inflammatory ATM phenotype, remain poorly understood.

1Department of Medicine, Marc and Ruti Bell Program for Vascular Biology and Disease, The Leon H. Charney Division of Cardiology, New York University Langone Health, New York, NY, USA. 2Department of Surgery, New York University Langone Health, New York, NY, USA. 3Department of Medicine, Division of Endocrinology, New York University Langone Health, New York, NY, USA. *email: bhama.ramkhalawon@nyumc.org; Kathryn.moore@nyumc.org
Macrophages can take on a spectrum of activation states to fulfill a broad range of functions needed for host defense, homeostasis, and tissue repair. In vitro characterization of macrophage activation programs has lead to the description of classically activated (by LPS + interferon-γ M1 macrophages [M1]) and alternatively activated (by IL-4) M2 macrophages (M2), which mediate pro- and anti-inflammatory macrophage functions. However, in vivo, there is likely an array of macrophage activation states that are dictated by the local tissue microenvironment. Indeed, gene expression profiling of ATM from obese mice and humans has shown that these macrophages have some, but not all, features of pro-inflammatory M1 macrophages. Recent studies indicate that rewiring of cellular energy metabolism is a key feature of macrophage activation that directly impacts macrophage phenotype and function. For example, alternatively activated M2 macrophages exhibit enhanced mitochondrial oxidative phosphorylation (OXPHOS) to fuel their function. By contrast, classically activated M1 macrophages have enhanced glycolysis that provides a rapid source of ATP to support their high secretory and phagocytic functions, and also feeds the pentose phosphate pathway to generate amino acids for protein synthesis, ribose for nucleotides and NADPH for the production of reactive oxygen species (ROS) by NADPH oxidase. Although these metabolic programs were originally thought to merely reflect the cell’s energy substrate utilization, recent studies using chemical or genetic inhibitors of glycolysis and fatty acid oxidation have shown that disrupting these programs can alter macrophage phenotype and inflammatory functions. Together, these findings have led to an appreciation that distinct bioenergetics profiles can guide macrophage functional responses in tissues, however the cellular metabolic programs of ATM are largely unexplored.

Hypoxia inducible factor 1 alpha (HIF-1α) is a potent transcriptional regulator of cellular adaptation programs required for growth and survival under hypoxic conditions, particularly the switch to glycolysis as OXPHOS becomes limited under low oxygen concentrations. Studies in obese mouse models and humans have documented the accumulation of HIF-1α in both adipocytes and ATM, and this has been attributed to oxidative stress that develops in the expanding adipose tissue. HIF-1α activation has also been shown to occur in LPS-activated macrophages under normoxic conditions (pseudohypoxia), which potentiates glycolytic flux at the expense of OXPHOS, and drives inflammatory gene expression, most notably of the pro-inflammatory cytokine IL-1β. This has been linked to the accumulation of TCA cycle intermediates, such as succinate, which along with ROS can stabilize HIF-1α by inhibiting prolyl hydroxylases (PHDs) that promote its degradation. Whether pseudohypoxia contributes to activation of HIF-1α in metabolically activated ATM, and their inflammatory response, is poorly understood.

Here, we hypothesize that in obesity, metabolic dysregulation leads to both hypoxic and pseudohypoxic stimuli that activate HIF-1α in ATM, thereby sustaining systemic low-grade inflammation, a condition that fuels insulin resistance. Characterization of the metabolic phenotype of ATM of lean and obese mice revealed that unlike M1 macrophages, which exhibit elevated glycolysis and impaired mitochondrial OXPHOS, ATM from high fat diet fed mice display increases in both glycolysis and OXPHOS programs compared to ATM from lean mice. Notably, HIF-1α, IL-1β and genes in the glycolysis pathway levels were increased in ATM isolated from white adipose tissue (WAT). Using a hypoxia tracer, we show that HIF-1α accumulates in both hypoxic and non-hypoxic ATM, suggesting that both low oxygen conditions and pseudohypoxia could contribute to HIF-1α driven inflammation in vivo. Incubating macrophages with palmitate, a saturated fatty acid released by adipocytes during lipolysis, under normoxic conditions, was sufficient to increase glycolysis and basal OXPHOS, as well as the HIF-1α and IL-1β production. Notably, the increased expression of IL-1β and genes in the glycolysis pathway induced by palmitate was reversed upon incubation with a HIF-1α inhibitor, implicating this transcription factor as a central regulator of the metabolically activated macrophage phenotype. Finally, we show that targeted deletion of HIF-1α, specifically in myeloid cells, reduced ATM accumulation in the WAT of high fat diet fed mice, as well as local and systemic IL-1β production, implicating HIF-1α as a guardian of metabolic stress and inflammation in obesity.

Results

Obesity reprograms cellular energy metabolism in adipose tissue macrophages. Recent studies indicate that rewiring of cellular energy metabolism can regulate macrophage phenotype and function, yet little is known about the metabolic programs that characterize ATM in obesity. To investigate this, we fed mice a low fat chow diet or a high fat diet for 20 weeks and isolated ATM from WAT. Flow cytometric characterization showed that 85–95% of these cells expressed the macrophage markers F4/80, MerTK and CD64, while less than 1% expressed the neutrophil marker Ly6G (Supplementary Fig. 1). Using Seahorse extracellular flux analyses we measured the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to determine OXPHOS and glycolysis, respectively. Compared to ATM from lean mice, ATM from obese mice showed an increase in both basal and maximal respiration, indicative of increased OXPHOS (Fig. 1a,b). As this finding may indicate an increase in mitochondrial mass in ATM from obese mice, we stained ATM isolated from lean and obese mice with mitotracker dye. We observed increased mitotracker staining in ATM isolated from obese compared to lean mice, indicative of elevated mitochondrial content in ATM residing in obese adipose tissue (Fig. 1c). Notably, ATM from obese mice also showed an increase in ECAR and glycolytic capacity compared to ATM from lean mice (Fig. 1d,e). This was consistent with increased levels of lactate, the by-product of glycolysis, in the stromal vascular fraction of WAT (Fig. 1f) and serum (Fig. 1g) of obese mice compared to lean mice. Together, these data suggest that ATM that accumulate in WAT undergo metabolic remodeling to support the biosynthetic and bioenergetic demands of the cell in the expanding adipose tissue.

Cellular metabolic programs can shape the activation and function of immune cells. For example, a potent transcriptional activator of glycolytic enzymes and inflammatory factors is the transcription factor HIF-1α. Immunofluorescence staining for HIF-1α and the macrophage marker F4/80 showed increased HIF-1α staining that co-localized with DAPI nuclear stain, indicative of active HIF-1α in the nucleus of macrophages in obese
Hypoxia fuels adipose tissue macrophage glycolysis and inflammation in vivo. A number of factors may drive HIF-1α activation and increased glycolysis in ATM of the expanding adipose tissue, including the development of hypoxia and stimuli that can promote a pseudohypoxic state by preventing HIF-1α activation and increased glycolysis in ATM of the expanding adipose tissue, including 

### Figure 1. (a-d) Seahorse analysis of cellular (a) oxygen consumption rate (OCR), (b) basal respiration, maximum respiration and spare respiratory capacity, (c) extracellular acidification rate (ECAR), and (d) glycolysis, glycolytic capacity and glycolytic reserve, in ATM from lean and obese wild type (WT) mice. Data are representative of 2 independent experiments from n = 2–3 mice/group. (e) Lactate levels in the stromal vascular fraction (SVF) of lean (n = 4) and obese mice (n = 5). (f) Serum lactate levels in lean (n = 6) and obese (n = 9) mice. Data are expressed as mean ± s.e.m. **p < 0.01, *p < 0.05.
Palmitate upregulates macrophage glycolysis and Hif-1α activation. During our analysis of WAT of obese mice injected with pimonidazole to detect hypoxic cells, we also noted increased Pkm2 and Glut1 mRNA levels in Pimo− cells isolated from lean adipose tissue suggesting a dynamic response to hypoxic stress (Supplementary Fig. 3). Furthermore, Pimo− ATM from WAT of obese mice showed increased expression of inflammatory cytokines, including Il1b, which is known to be regulated by HIF-1α in highly glycolytic M1 macrophages (Fig. 3f), as well as Il6 and Tnfa mRNAs. These studies implicate hypoxia-driven glycolysis as a regulator of the inflammatory phenotype of M1 in obese adipose tissue.

Pkm2, Pykf3 compared to Pimo− ATM from the same mice (Fig. 3e). We also noted increased Pkm2 and Glut1 mRNA levels in Pimo− cells isolated from lean adipose tissue suggesting a dynamic response to hypoxic stress (Supplementary Fig. 4). Furthermore, Pimo− ATM from WAT of obese mice showed increased expression of inflammatory cytokines, including Il1b, which is known to be regulated by HIF-1α in highly glycolytic M1 macrophages (Fig. 3f), as well as Il6 and Tnfa mRNAs. These studies implicate hypoxia-driven glycolysis as a regulator of the inflammatory phenotype of M1 in obese adipose tissue.

During our analysis of WAT of obese mice injected with pimonidazole to detect hypoxic cells, we also noted increased Pkm2 and Glut1 mRNA levels in Pimo− cells isolated from lean adipose tissue suggesting a dynamic response to hypoxic stress (Supplementary Fig. 3). Furthermore, Pimo− ATM from WAT of obese mice showed increased expression of inflammatory cytokines, including Il1b, which is known to be regulated by HIF-1α in highly glycolytic M1 macrophages (Fig. 3f), as well as Il6 and Tnfa mRNAs. These studies implicate hypoxia-driven glycolysis as a regulator of the inflammatory phenotype of M1 in obese adipose tissue.
on glycolysis (Fig. 5e). Furthermore, we found that palmitate-BSA increased the secretion of IL-1β protein by BMDMs, compared to control BSA treatment, and this was blocked by pretreatment of macrophages with 2-DG or a HIF-1α inhibitor (Fig. 5f). Together, these results link palmitate-induced glycolysis or HIF-1α activation to the induction of IL-1β in macrophages.
Figure 5. (a,b) Seahorse analysis of (a) extracellular acidification rate (ECAR) and (b) glycolysis, glycolytic capacity and glycolytic reserve in BMDM treated with 50, 100 or 250 μM BSA-conjugated palmitate or 250μM BSA alone. (c,d) Seahorse analysis of (c) oxygen consumption rate (OCR) and (d) basal respiration, maximum respiration and spare respiratory capacity in BMDM treated as indicated. (e) Relative mRNA expression of inflammatory cytokines in BMDM treated with 250μM BSA or BSA-conjugated palmitate in the presence and absence of 2-deoxyglucose (2-DG). Levels of IL-1β protein in the supernatant of BMDM treated with BSA or BSA-palmitate in the presence of absence of (f) 2-DG or (g) a HIF-1α inhibitor. Data are representative of 3 independent experiments and are expressed as mean ± s.e.m. *p < 0.05.

HIF-1α deletion in myeloid cells induces a phenotypic switch in ATM and tempers WAT inflammation. We next tested the effects of macrophage-specific deletion of HIF-1α on obesity related inflammation and metabolic dysfunction. We fed Hif1α<sup>LysMcre</sup> (HKO) and Hif1α<sup>LysMcre</sup>−/− (WT) mice a low fat chow or high fat diet for 20 weeks. Although no difference in weight gain or fat mass was observed in WT and HKO mice on the HFD, HKO mice fed chow diet had a modest reduction in weight and adipose mass compared to WT mice on chow diet (Fig. 6a,b), which was confirmed by dual-energy X-ray absorptiometry (DEXA) (Fig. 6c). Uncoupling protein 1 (Ucp1) mRNA levels in WAT of KO lean mice was increased compared to WT mice, consistent with an induction of local thermogenesis that could lead to reduced WAT weight in lean HKO mice. Notably, Ucp1 mRNA expression was decreased in WAT of HFD fed WT and HKO mice compared to chow fed WT and HKO mice, and no difference was observed between the genotypes in the HFD-fed groups (Supplementary Fig. 5a). Brown adipose tissue (BAT) mass was increased upon HFD feeding but no difference was observed between the genotypes studied (Supplementary Fig. 5b). Despite similar adiposity in WT and HKO mice after HFD feeding, we observed a decrease in F4/80<sup>+</sup> macrophage accumulation in WAT of HKO mice as measured by immunofluorescence staining (Fig. 6d). To investigate the mechanisms contributing to the reduced numbers of F4/80<sup>+</sup> cells in HKO HFD-fed mice compared to WT mice, we measured markers of macrophage proliferation and retention. We observed a decrease in the proliferation marker Ki67 in WAT of HFD-fed HKO compared to WT mice (Fig. 6e, Supplementary Fig. 5c) suggesting that macrophage proliferation is reduced in the absence of HIF-1α. Furthermore, we also observed a decrease in the expression of the neuroimmune guidance cue netrin-1, which promotes macrophage survival and tissue retention<sup>23,24</sup>, in HFD-fed HKO compared to WT mice (Fig. 6f). These findings are consistent with previous studies showing that expression of netrin-1 is regulated in macrophages<sup>25</sup>. These data suggested that targeted deletion of HIF-1α in macrophages reduced the accumulation of these cells in the WAT during obesity.

Consistent with previous studies we observed an increase in the expression of the macrophage pro-inflammatory mediators, Ccl2, Il6 and Il1b in the WAT of WT mice fed HFD compared to chow diet (Fig. 7a). While we observed no difference in Ccl2 and Il6 mRNA levels in the WAT of HKO and WT mice fed HFD, Il1b mRNA expression was selectively reduced in WAT of HKO mice compared to their WT counterparts. Furthermore, the decreased expression of Il1b mRNA in WAT correlated with decreased serum levels of IL-1β in HFD-fed HKO mice compared to HFD-fed WT, as measured by cytometric bead array assay (Fig. 7b). To further understand the effects of HIF-1α deletion on macrophage inflammatory status in WAT during obesity,
we measured the expression of a panel of markers that characterize alternatively activated macrophages. The absence of HIF-1α in macrophages enhanced the expression of Mr1, Arg1 andFizz1 mRNA in the WAT of HKO mice compared to WT mice fed HFD (Fig. 7c), suggesting increased accumulation of alternatively activated macrophages known to mediate tissue repair. Interestingly, despite these improvements in WAT inflammation and local and systemic IL-1β expression in HFD-fed HKO mice, we observed no significant difference in insulin sensitivity compared to WT mice (Fig. 7d), although there was a trend towards improved glucose tolerance in HFD-fed HKO compared to WT mice (Fig. 7e). Together, these data indicate that HIF-1α drives macrophage expression of IL-1β in the obese adipose tissue, leading to increased concentrations of IL-1β in the plasma. While deletion of HIF-1α reduces local and systemic IL-1β levels, and causes an enrichment of M2 macrophages in the WAT, this is not sufficient to reverse the metabolic dysfunction associated with obesity.

**Discussion**

Targeting immunometabolism in chronic inflammatory diseases has emerged as a promising new therapeutic avenue. Recent studies using microbial or cytokine stimuli have begun to establish metabolic signatures for different types of in vitro activated macrophages⁹,¹²,¹³. However, tissue microenvironmental cues are important regulators of macrophage metabolism and thus, understanding the metabolic behaviours of tissue macrophages is of fundamental importance in designing new therapeutic approaches. Here we defined the metabolic programs engaged in adipose tissue macrophages in the context of obesity, and demonstrated that this is directly linked to their proinflammatory phenotype via the transcription factor HIF-1α.

Recent studies have shown that macrophages that accumulate in WAT during obesity have an activated phenotype that shares some, but not all features of classically activated LPS-treated macrophages⁹,¹⁰. Indeed, while macrophages acutely stimulated with LPS undergo a profound shift in metabolism towards glycolysis at the expense of OXPHOS, we show that ATM isolated from obese mice exhibit upregulation of both glycolysis and OXPHOS as measured by Seahorse Bioenergetic Analysis. These findings are consistent with those of Stienstra and colleagues, who recently published a transcriptomic analysis of ATM that showed upregulation of genes involved in both glycolysis and OXPHOS in ATM of obese compared to lean mice - changes that were distinct from those observed in LPS-stimulated macrophages⁹. Interestingly, this metabolic rewiring in response to HFD-feeding was tissue specific, as peritoneal macrophages from obese mice did not exhibit similar transcriptomic changes. Furthermore, consistent with the metabolic phenotype that we measured in ATM isolated directly from obese adipose tissue, the authors showed that bone marrow-derived macrophages co-cultured with adipose tissue explants from obese mice exhibited enhanced glycolysis and OXPHOS compared with bone marrow derived macrophages exposed...
to lean adipose tissue\textsuperscript{26}. A similar boost of both glycolysis and OXPHOS has been observed in macrophages treated with TLR2 ligands such as Pam3Cys\textsuperscript{27}, and this metabolic rewiring in ATM likely results from local cues in the tissue microenvironment. Notably, ATM in the obese adipose tissue are exposed to products of adipocyte lipolysis, such as free fatty acids, and exhibit increased lipid metabolism and lysosomal function\textsuperscript{8,14}, which may help fuel fatty acid oxidation\textsuperscript{16}. OXPHOS, although slower than glycolysis, also produces greater amounts of ATP from glucose, and has been shown to be required for key macrophage functions such as phagocytosis, which is upregulated as ATM encounter dying adipocytes. Consistent with the coincident upregulation of glycolytic metabolism in ATM, we observed increased levels of its by-product, lactate, in the WAT stromal vascular fraction and serum of obese mice and high concentrations of lactate have also been reported in obese humans\textsuperscript{28}. An upregulation of the glycolytic rate appears to be a common response of activated macrophages challenged with different inflammatory stimuli\textsuperscript{17, 18}. Although glycolysis is far less efficient in generating ATP than oxidative phosphorylation, this metabolic adaptation can also fuel glycolysis intermediates into the pentose phosphate pathway and provides building blocks needed for macrophage activation, such as amino acids for protein synthesis, ribose for nucleotides, and NADPH for the production of reactive oxygen species\textsuperscript{12, 15}. Thus, the upregulation of both oxidative phosphorylation and glycolysis programs in ATM likely fuels key functions needed for adaptation of these macrophages in the obese adipose tissue.

Metabolic rewiring of macrophages towards glycolysis has been shown to influence immune cell function. In LPS-stimulated macrophages, accumulation of glycolytic intermediates and ROS can inhibit prolyl hydroxylases that degrade HIF-1α\textsuperscript{17}, leading to HIF-1α accumulation and increased expression of the glycolytic machinery. This mechanism of HIF-1α stabilization, termed pseudohypoxia, has been shown to drive expression of IL-1β\textsuperscript{15}, a potent inflammatory cytokine that has been implicated in obesity related insulin resistance\textsuperscript{12, 29}. Notably, we find that ATM isolated from obese mice show a similar pattern of enhanced glycolysis, HIF-1α accumulation and increased IL-1β expression. In the obese adipose tissue microenvironment ATM may be exposed to multiple stimuli that provoke HIF-1α adipose tissue microenvironment ATM may be exposed to multiple stimuli that provoke HIF-1α activation in the absence of reduced oxygen levels. Our data provide indications that free fatty acids released from obese adipocytes and the accumulation of metabolic cycle intermediates, such as succinate and glutamate, could perform such roles. This metabolic program could be provoked \textit{in vitro} by stimulating macrophages with palmitate, a saturated fatty acid that is present at increased levels in the circulation of high-fat-diet-fed mice. Palmitate dose-dependently upregulated the macrophage glycolytic rate, leading to activation of HIF-1α, and

---

**Figure 7.** (a) Relative mRNA expression of \(Ccl2\), \(Il6\) and \(Il1b\) in WAT of wild type (WT) and Hif1a\textsuperscript{fl/fl}LysMcre+ (HKO) on chow or HFD diet for 20 weeks. (b) Plasma levels of IL-6 and IL-1β in WT and HKO mice on chow or HFD for 20 weeks. (c) Relative mRNA expression of Mr1, Arg1, and Fizz1 in WAT of WT and HKO mice fed chow or HFD for 20 weeks. (d) Glucose tolerance test (GTT) and (e) insulin tolerance test (ITT) of WT (\(n=11\)) and HKO (\(n=10–12\)) mice fed chow or HFD diet for 20 weeks. Data are expressed as the mean ± s.e.m. ***\(p<0.0001\), **\(p<0.001\), *\(p<0.01\), *\(p<0.05\).
increased expression of IL-1β in addition palmitate increased expression of HIF-1α-target genes in the glycolytic pathway, including the glucose transporter Glut1 and key glycolytic enzymes, which would in turn reinforce aerobic glycolysis. Importantly, we showed that the upregulation of IL-1β and glycolytic genes by palmitate could be blocked by chemical inhibitors of either glycolysis or HIF-1α.

Although our data provide evidence for a role of pseudohypoxia in the induction of IL-1β in ATM, we cannot exclude the contribution of other immune cells, such as eosinophils and dendritic cells, in this context. In this study, we used F4/80 as a marker for macrophages, but this marker can also be expressed by some dendritic cells and eosinophils. Using flow cytometric analysis we showed that 95% of CD11b+ F4/80+ cells in obese mice are also positive for the macrophage markers CD64 and MerTK, suggesting that the contribution of other cell types is minor. In addition, HIF-1α activation in ATM is also likely to also be potentiated by low oxygen tensions that occur in the rapidly expanding adipose tissue in vivo. Indeed, isolation of hypoxic ATM from WAT of obese mice showed high levels of HIF-1α and IL-1β expression, compared to non-hypoxic ATM from the same tissue. Hypoxia is also a driver of glycolysis, and we observed increased expression of the glucose transporter Glut1 and glycolytic enzymes in hypoxic compared to non-hypoxic ATM. These data suggest that multiple mechanisms likely sustain glycolysis in ATM, with activation of HIF-1α and induction of IL-1β expression as a common consequence of this metabolic reprogramming.

Considerable evidence points to a role for IL-1β in the development of insulin resistance and type 2 diabetes. Low grade inflammation has been shown to precede the development of type 2 diabetes, and elevated levels of IL-1β in the circulation are associated with increased risk. Studies using obesity- and diabetes-associated ligands have identified roles for palmitate, insulin associated polypeptide (IAPP), and ceramide in activating the NLRP3 inflammasome complex required for IL-1β maturation and secretion. IL-1β is a potent inflammatory cytokine that can amplify the production of other inflammatory mediators, such as TNF-α and IL-6, via signalling through the IL-1 receptor, and can also increase hepatocies. Furthermore, studies that block IL-1β production using genetic deletion of components of the NLRP3 inflammasome that regulates IL-1β maturation or inhibition of the IL-1β signaling machinery have established a role for this cytokine in promoting insulin resistance and metabolic dysfunction in high fat diet fed mice, as well as conditions accelerated by diabetes such as atherosclerosis. These studies have led to thinking that pharmacological approaches to treat diabetes should not only correct hyperglycaemia, but also attenuate inflammation to prevent the development of metabolic and cardiovascular complications.

To test whether targeting macrophage immunometabolism could block the production of IL-1β and its inflammatory and metabolic sequelae, we generated mice lacking HIF-1α specifically in myeloid cells and challenged them to high diet feeding. We found that targeted deletion of myeloid HIF-1α significantly reduced macrophage accumulation in the WAT, without altering weight gain or adiposity, as compared to WT mice. Furthermore, mice with myeloid HIF-1α deficiency showed lower levels of IL-1β expression in both WAT and the circulation than WT mice, consistent with HIF-1α being a key mechanism underlying IL-1β expression in the setting of obesity. The reduction of systemic levels of IL-1β in myeloid HIF-1α KO mice implicates macrophages as a major source of this cytokine in vivo during high fat diet feeding. Moreover, the reduced ATM accumulation in myeloid HIF-1α null mice suggests that the HIF-α–IL-1β axis amplifies macrophage burden in the WAT, a finding supported by previous studies showing that IL-1β promotes myelopoiesis, thereby enhancing the supply of monocytes to WAT. In addition to the decrease in IL-1β expression in ATM, we observed an increase in markers of alternatively activated M2 macrophages in the WAT of HFD-fed mice with myeloid deficiency of HIF-1α compared to WT mice, suggesting that loss of HIF-1α leads to a less inflammatory macrophage phenotype in the adipose tissue. As HIF-1α drives glycolysis, this shift in ATM polarization toward an M2-like macrophage phenotype in its absence may result from a metabolic reprogramming toward OXPHOS, which has been shown to drive alternative activation.

Despite reducing WAT inflammation and systemic levels of IL-1β, the conditional deletion of HIF-1α in myeloid cells, however, was not sufficient to reverse the impairment of glucose clearance and insulin tolerance associated with high fat diet feeding in this study. Notably, our findings differ from a recent report that myeloid deficiency of HIF-1α improved systemic insulin resistance, as well as WAT inflammation, in a similar model of diet-induced obesity. While the reasons for these discrepant findings are unclear, they may arise from differences in the diet used or the microbiome of the mice housed in different facilities. Nevertheless, studies of selective HIF-1α-deficiency in other cell types in the adipose tissue, most notably adipocytes, has been shown to protect against insulin resistance, suggesting that targeting HIF-1α broadly in WAT may be a strategy to improve both inflammation and metabolic dysfunction. Collectively, our data identify enhanced glycolysis and HIF-1α activation in ATM as key mechanisms underlying macrophage persistence in the WAT and the local and systemic expression of IL-1β, placing these immunometabolic signals at the interface of macrophage activation in obesity.

**Materials and Methods**

**Mice.** The Institutional Animal Care and Use Committee of New York University Medical Center approved all animal experiments. All methods were performed in accordance with New York University Medical Center guidelines and regulations. The Hif1α−/− and LysMCre transgenic mice were purchased from Jackson laboratory and mated to generate Hif1α+/−;LysMCre+ mice (HKO) and Hif1α−/−;LysMCre– control mice. The mice were maintained under a standard light cycle (12 h light/dark) and were allowed free access to water and food. They were fed a low fat chow diet 13.2% calories from fat, 24.6% protein, 62.1% carbohydrate (PicoLab Rodent Diet 20) or a high fat diet (HFD) containing 60% calories from fat, 20% protein, 20% carbohydrate (Research Diets, D12492). After feeding, the body composition and % adiposity of mice was analysed by dual-energy X-ray absorptiometry (DEXA) scanning. Glucose-tolerance tests were performed as previously described. After determination of fasted blood glucose levels, each animal received a glucose gavage of 1.5 g/kg body weight of glucose.
Isolation of CD11b+ cells from the SVF was performed by magnetic immunoaffinity isolation with anti-CD11b antibodies conjugated to magnetic beads (10 µg). Then, the cells were spun at 300 g for 5 minutes to separate floating adipocytes from the stromal vascular fraction (SVF) pellet.

**Hypoxia probe.** Hypoxprobe™ (pimonidazole hydrochloride; Hypoxyprobe, Inc. MA, USA) immunohistochemical and flow cytometry analyses were used to assess hypoxia in cells and tissues as we previously described. Pimonidazole is a 2-nitroimidazole that is reductively activated in hypoxic cells and forms stable adducts with thiol groups in proteins, peptides, and amino acids. Pimonidazole hydrochloride was injected intraperitoneally at a dose of 120 mg/kg body weight 60 min before tissue collection. Anti-pimonidazole antibody (clone 4.3.11.3, MAb1, Hypoxyprobe, Inc. MA, USA) was used to detect pimonidazole positive regions.

**Primary cell culture.** For adipose tissue macrophage purification, visceral fat pads of mice fed were excised, minced in Hank’s Balanced Salt Solution (HBSS) and centrifuged at 500 g for 5 minutes to remove erythrocytes and free leukocytes. Liberase (5401119001; Roche applied science) was added to tissue suspensions at 1 mg/ml and incubated at 37 °C for 30 minutes with shaking. The tissue suspension was filtered through a 100-µm filter and then spun at 300 g for 5 minutes to separate floating adipocytes from the stromal vascular fraction (SVF) pellet. Isolation of CD11b+ cells from the SVF was performed by magnetic immunoaffinity isolation with anti-CD11b antibodies conjugated to magnetic beads (10 µl/10⁷ cells, 120-000-300; MACS Miltenyi Biotech). Cells were isolated using positive selection columns (LS Columns, 130-042041, MACS Miltenyi Biotech) prior to preparation of whole-cell lysates.

For primary bone marrow derived macrophages (BMDM) preparation, the bone marrow of the tibia and femur of 6–8 week old C57Bl/6 mice was flushed using ice-cold DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were plated overnight in DMEM supplemented with 20% L929-conditioned media, 10% FBS and 1% penicillin/streptomycin, and non-adherent cells were removed and cultured further for 7 days as we described. For Seahorse extracellular flux (XF) analysis, BMDM were stimulated with 50–250 µM BSA-conjugated palmitate or BSA as a control for 24 h and the Seahorse XF Mito stress test (OCR; oxygen consumption rate) (Agilent technologies, CA, USA) were performed as described previously. For gene expression analyses, BMDM were treated with 250 µM BSA-conjugated palmitate or BSA for 24 hours and RNA was isolated. In some assays, BMDM were also treated with 2-deoxyglucose or HIF-1α inhibitor for 24 hours (100 µM, #400083, Calbiochem).

**Palmitate-BSA preparation.** Sodium palmitate (P9767; Sigma Aldrich, MO, USA) was dissolved in sterile water to make a 100 mM solution by alternating heating and vortexing until the palmitate was dissolved. This occurred once the solution reached 70 °C. Immediately after the palmitate dissolved, it was conjugated to serum-free DMEM containing 5% NEFA-free BSA, creating a 5 mM palmitate solution as described. The 5 mM palmitate solution was shaken at 140 rpm at 40 °C for 1 h and was then immediately used to treat the cells. Serum-free DMEM containing 5% NEFA-free BSA was used as the vehicle control.

**Real-time quantitative RT-PCR analysis.** Total RNA was isolated using TRIzol reagent (Invitrogen) and Direct-zol RNA MiniPrep columns (Zymo Research). For mRNA quantification, RNA (0.5–1 µg) was reverse transcribed using iScript™ cDNA Synthesis Kit (Biorad, CA, USA) and quantitative real-time (qRT) PCR was performed in triplicate using kapa SYBR green Supermix (Kappa Biosystems, MA, USA) and a QuantStudio 3 Real-Time PCR system (ThermoFisher Scientific, MA, USA) as we previously described. The primers used are listed in Supplemental Table 1. Fold change in mRNA expression was calculated normalized to 28S using the comparative cycle method (ΔΔCt).

**Immunohistochemistry.** White adipose tissue was excised, fixed in formalin overnight, embedded in paraffin and sectioned. The immunofluorescence analysis of F4/80 (MCA195G; AbD Serotec, NC, USA), lactate dehydrogenase (ab47010, Abcam) and HIF-1α (NB100-479; Novus Biosciences, CO, USA) was conducted after deparaffinization as described previously. Sections were mounted and visualized using a Nikon Eclipse microscope.

**Western-blot analysis.** BMDMs treated with palmitate were homogenized in lysis buffer as previously described and subjected to SDS-PAGE analysis. Western blot analysis was carried out using anti-HIF-1α (Novus Biosciences) and α-tubulin (T6074; Sigma Aldrich) as loading control.

**Statistical methods.** The difference between two groups was analyzed by Student’s t-test or for multiple comparisons, by one-way analysis of variance, followed by Newman-Keus multiple comparison test. P values of less than 0.05 were considered significant.

Received: 4 May 2018; Accepted: 10 March 2020;
Published online: 27 March 2020
References

1. Hales, C. M., Carroll, M. D., Fryar, C. D. & Ogden, C. L. Prevalence of Obesity Among Adults and Youth: United States, 2015–2016. NCHS Data Brief, 1–8 (2017).
2. Hotamisligil, G. S. Foundations of Immunometabolism and Implications for Metabolic Health and Disease. *Immunity* 47, 406–420, https://doi.org/10.1016/j.immuni.2017.08.009 (2017).
3. Odegaard, J. I. & Chawla, A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. *Science* 339, 172–177, https://doi.org/10.1126/science.1230721 (2013).
4. Lee, Y. S. et al. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. *Diabetes* 60, 2474–2483, https://doi.org/10.23736/s1144-0142.11-0194 (2011).
5. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* 112, 1796–1808, https://doi.org/10.1172/JCI19246 (2003).
6. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J. Clin. Invest.* 112, 1821–1830, https://doi.org/10.1172/JCI19451 (2003).
7. Hill, A. A., Reid Bolus, W. & Hasty, A. H. A decade of progress in adipose tissue macrophage biology. *Immunol. Rev.* 262, 134–152, https://doi.org/10.1111/imr.12216 (2014).
8. Kratz, M. et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. *Cell Metab.* 20, 614–625, https://doi.org/10.1016/j.cmet.2014.08.010 (2014).
9. Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J. Clin. Invest.* 117, 175–184, https://doi.org/10.1172/JCI29881 (2007).
10. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* 259, 87–91 (1993).
11. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. *Nat. immunology* 12, 408–415, https://doi.org/10.1038/ni.2022 (2011).
12. Stienstra, R., Netea-Maier, R. T., Riksen, N. P., Joosten, L. A. B. & Netea, M. G. Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during Innate Immune Responses. *Cell Metab.* 26, 142–156, https://doi.org/10.1016/j.cmet.2017.06.001 (2017).
13. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 41, 14–20, https://doi.org/10.1016/j.immuni.2014.06.008 (2014).
14. Xu, X. et al. Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. *Cell Metab.* 18, 816–830, https://doi.org/10.1016/j.cmet.2013.11.001 (2013).
15. Van den Bossche, J., O’Neill, L. A. & Menon, D. Macrophage Immunometabolism: Where Are We (Going)? *Trends Immunol.* 38, 395–406, https://doi.org/10.1016/j.it.2017.03.001 (2017).
16. Huang, S. C. et al. Cellular lysosomal lipolysis is essential for alternative activation of macrophages. *Nat. immunology* 15, 846–855, https://doi.org/10.1038/ni.2956 (2014).
17. Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. *Nature* 496, 238–242, https://doi.org/10.1038/nature12186 (2013).
18. Quinet M. et al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. *J. Clin. Invest.* 135, 81676, doi: 10.1172/JCI81676 (2015).
19. Corcoran, S. E. & O’Neill, L. A. HIF1alpha and metabolic reprogramming in inflammation. *J. Clin. Invest.* 126, 3699–3707, https://doi.org/10.1172/JCI84431 (2016).
20. Hosogai, N. et al. Macrophage accumulation in adipose tissue is associated with inflammatory responses in human obesity and obesity-related insulin resistance. *J. Clin. Invest.* 128, 852–864, https://doi.org/10.1172/JCI102615 (2018).
21. van Gils, J. M. et al. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the migration of macrophages from plaques. *Nat. immunology* 13, 136–143, https://doi.org/10.1038/nni.2205 (2012).
22. Ramkhalawon, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Nat. Immunol.* 17, 548–553, https://doi.org/10.1038/ni.1935 (2010).
23. Perez de Heredia, F., Wood, I. S. & Trayhurn, P. Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. *Pflug. Arch.* 459, 509–518, https://doi.org/10.1007/s00424-009-0750-3 (2010).
24. Sauter, N. S., Schultz-Thile, F. T., Galasso, R., Castellani, L. W. & Maedler, K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. *Endocrinology* 149, 2208–2218, https://doi.org/10.1210/en.2007-0509 (2008).
25. Kumar, A. & Rader, D. J. Effect of interleukin 1beta inhibition in cardiovascular disease. *Curr. Opin. Lipidol.* 23, 548–553, https://doi.org/10.1097/MOL.0b013e328359b0a6 (2012).
26. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* 464, 1357–1361, https://doi.org/10.1038/nature08938 (2010).
27. Takkakwa, A. et al. HIF-1alpha in Myeloid Cells Promotes Adipose Tissue Remodeling Toward Insulin Resistance. *Diabetes* 65, 3649–3659, https://doi.org/10.23736/s1144-0142.15-00112 (2016).
28. Lee, Y. S. et al. Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. *Cell* 157, 1339–1352, https://doi.org/10.1016/j.cell.2014.05.012 (2014).
39. Gundra, U. M. et al. Vitamin A mediates conversion of monocyte-derived macrophages into tissue-resident macrophages during alternative activation. *Nat. Immunology* 18, 642–653, https://doi.org/10.1038/ni.3734 (2017).

40. Raleigh, J. A. & Koch, C. J. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. *Biochem. Pharmacol.* 40, 2457–2464 (1990).

**Acknowledgements**
Support for this work came from the National Institutes of Health (R01 DK111211 to KJM, P01 HL131481 to KJM and EAF) and Canadian Institutes of Health Research (Doctoral Award to GK). We thank the New York University Langone Medical Center Immune Monitoring Core for the use of the XF’24 Extracellular Flux Analyzer (supported by the NYU-HHC CTSI Grant UL1 TR000038 and the NYU Cancer Institute’s Cancer Center Support Grant P30CA016087).

**Author contributions**
B.R. and K.J.M. designed the study, supervised the experiments and wrote the manuscript. B.R., M.S., R.S., S.H., L.B., B.Y. and W.S. performed the high fat diet feeding experiments and analysed those data; M.S., M.O., L.B., and B.R. performed Seahorse extracellular flux analysis, G.K. and M.S. performed CBA experiments, B.R. performed immunostaining, L.S. and T.H. performed flow cytometry staining and sorting. E.A.F. and R.R. provided advice in selected experimental areas and drafting of the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-62272-9.

**Correspondence** and requests for materials should be addressed to B.R. or K.J.M.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020